Petach Tikva, Israel (OTE) – Strategic appointments reflect Medison’s
continued investment in
global scale and operational excellence
Medison , the creator of a first-of-its-kind unified global
commercialization platform that accelerates the launch of
breakthrough therapies in markets beyond the U.S., Western Europe,
and Japan, today announced two key additions to its global leadership
team: Shay Tamari as Chief Business Officer (CBO) and Tali Mirsky as
Chief Legal & Compliance Officer (CLCO).
Medison’s platform enables biotech companies to plan, optimize,
and launch their breakthrough therapies globally by utilizing
Medison’s end-to-end, seamless, affiliate-like model through a
single, unified, centrally managed partnership.
Reinforcing global capabilities for long-term growth
As Medison continues to scale its operations and deepen
partnerships with biotech companies around the world, strengthening
its leadership capacity is essential to delivering sustainable value
and impact. Shay and Tali bring extensive global experience and
strategic insight that will support the company’s ability to execute
across geographies, navigate increasing complexity, and uphold the
highest standards of trust, ethics, and performance.
Shay Tamari, newly appointed Chief Business Officer, will lead
Medison’s global corporate development strategy. With over 20 years
of international experience in the pharmaceutical industry, including
a decade at Pfizer and a deep understanding of the U.S. biotech
ecosystem, Shay will focus on unlocking long-term growth
opportunities, fostering strategic partnerships, and amplifying the
reach of Medison’s platform. Based in the U.S., Shay brings valuable
proximity to major biotech hubs and industry partners.
Tali Mirsky joins as Chief Legal & Compliance Officer, bringing
more than 25 years of legal and compliance expertise, in both private
and publicly traded companies, most recently from NICE. Her
leadership in strategic global transactions, corporate governance,
risk management and compliance will support Medison’s expansion and
further reinforce the integrity of our unique platform, ensuring we
uphold the highest standards of governance, compliance, and ethics
while operating in diverse international markets.
„We are excited to welcome Shay and Tali to Medison’s leadership
team,“ said Gil Gurfinkel, CEO of Medison. „Their experience in
leading public companies and their deep industry expertise will be
instrumental as we continue to scale our operations and bring
breakthrough therapies to patients in underserved markets around the
world. These appointments reflect our ongoing commitment to deliver
on our ambitious mission.“
„We have been building one-of-its-kind global commercial platform
and we bring the best talent to support its expansion“ added Meir
Jakobsohn, Founder and Executive Chairman of Medison, „our leadership
is committed to making breakthrough therapies accessible to patients
with rare and severe diseases regardless of where they live.“
„I am thrilled to join Medison at such a pivotal time in its
journey,“ said Shay Tamari, Chief Business Officer. „Medison’s unique
platform and vision for global biotech commercialization are both
compelling and needed. I look forward to working with the team to
deepen our partnerships and expand access to breakthrough therapies
for patients.“
„Medison is redefining what global biotech commercialization can
look like, and I am proud to be part of that,“ said Tali Mirsky,
Chief Legal & Compliance Officer. „I look forward to supporting the
company’s next phase of growth by reinforcing commercial and
operational excellence and upholding the highest standards of
compliance and ethics.“
Advancing a new global model for biotech commercialization These
appointments reflect Medison’s commitment to building an unmatched
global leadership team to power its platform. With Shay and Tali on
board, Medison is further strengthening its ability to help its
biotech partners bring breakthrough therapies to more patients, in
more places – delivering meaningful impact across regions that have
long been underserved.
About Medison Medison is redefining global biotech
commercialization to change lives.
As the first-of-its-kind unified global commercialization
platform, Medison partners with biotech companies to bring
breakthrough therapies to patients worldwide, especially those with
severe and rare diseases.
We specialize in accelerating access and expanding reach in
markets beyond the U.S., Western Europe, and Japan. Our unique
affiliate-like model seamlessly integrates commercial, medical, and
operational capabilities across diverse regions, enabling biotech
innovators to scale globally without compromising on local impact.
By applying creativity, expertise, passion, and a borderless
mindset, we’re accelerating access to breakthrough therapies—bringing
hope to more lives in more places.
We strongly believe that every patient deserves the same chance
at a full life, no matter where they live, and we are here to make
that belief a reality.
Digital press kit: http://www.ots.at/pressemappe/PR150016/aom
